Agomelatine Market Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The agomelatine market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Agomelatine is an atypical antidepressant used to treat major depressive disorder and it is used to treat depression. The growth of the market is attributed to various factors such as an increase in the prevalence of hypertension and other cardiovascular diseases, a rise in awareness about the benefits of agomelatine drugs, and increasing expenditure by pharmaceutical companies. Moreover, the increase in the prevalence of anxiety disorder has created a demand for the development of new receptors for its treatment which in turn drives the global agomelatine market growth.

According to the data published by the Anxiety & Depression Association of America (ADAA) in 2021, anxiety disorders are the most common mental illness in the US, affecting 40 million adults at age 18 years and older, or 18.1% of the population. They are highly treatable, yet only 36.9% of those suffering receive treatment. Generalized Anxiety Disorder (GAD) affects approximately 6.8 million adults or 3.1% of the US population, Panic Disorder (PD) affects 6 million adults or 2.7% of the US population, whereas Society Anxiety Disorder (SAD) affects 15 million adults or 6.8% of the US population. Thus, as per AADA, people with anxiety disorders are three to five times more likely to visit a doctor and six times more likely to be hospitalized for physiatric disorders than those who do not suffer from an anxiety disorder. Thus, the rise in the prevalence of anxiety disorders is anticipated to fuel the demand for the global agomelatine market during the forecast period.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape-AbbVie Inc., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly & Co., Takeda Pharmaceutical Co. Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Agomelatine Market Report by Segment

By Type

• Serotonin 2C Agonist
• Melatonin Receptor 2 Agonist
• Melatonin Receptor 1 Agonist
• Serotonin Receptor Agonist
• Serotonin 2C Receptor Antagonist

By Application

• Depression
• Obsessive-Compulsive Disorder
• Sleep Disorders
• Generalized Anxiety Disorder
• Multiple Sclerosis
• Systemic Traumatic Pain
• Autism
• Other